Anaptys Announces Participation in December Investor Conferences

Rhea-AI Summary

Anaptys (Nasdaq: ANAB) said CEO Daniel Faga and other executives will participate in multiple December investor conferences, including a fireside chat and 1x1 meetings at the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 1:30 PM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 3, 2025 at 7:55 AM ET.

Live webcasts of the fireside chats will be available on the company investor website and replays will be available for at least 30 days after each event.

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

Piper Sandler 37th Annual Healthcare Conference, New York, NY

• Format – Fireside chat and 1x1 investor meetings
• Date and Time – Tuesday, Dec. 2, 2025 at 1:30pm ET
  

Evercore 8th Annual Healthcare Conference, Coral Gables, FL

• Format – Fireside chat and 1x1 investor meetings
• Date and Time – Wednesday, Dec. 3, 2025 at 7:55am ET

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here.

Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com

FAQ

When will Anaptys (ANAB) present at the Piper Sandler 37th Annual Healthcare Conference?

Anaptys will present on Dec 2, 2025 at 1:30 PM ET with a fireside chat and 1x1 investor meetings.

What is the date and time for Anaptys (ANAB) at the Evercore 8th Annual Healthcare Conference?

Anaptys is scheduled for a fireside chat and 1x1 meetings on Dec 3, 2025 at 7:55 AM ET.

Where can investors watch the Anaptys (ANAB) fireside chats live on Dec 2–3, 2025?

Live webcasts will be available on Anaptys' investor site at https://ir.anaptysbio.com/presentations-and-events.

How long will replay access be available for Anaptys (ANAB) conference webcasts?

Replays of the fireside chat webcasts will be available for at least 30 days after each event.

Who from Anaptys will participate in the December 2025 investor conferences?

Daniel Faga, president and chief executive officer, and/or other members of Anaptys' executive leadership team will participate.